B. Riley Securities Maintains Buy on Denali Therapeutics, Raises Price Target to $35

Benzinga Newsdesk www.benzinga.com Positive 80.3%

Neg 0% Neu 0% Pos 80.3%

B. Riley Securities analyst Mayank Mamtani maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $30 to $35.